iECURE
Gabriel M. Cohn, M.D., MBA, is the Chief Medical Officer of iECURE. He brings more than 30 years of experience in academic medicine and the biotechnology industry and has contributed to the development of multiple therapeutics for the treatment of rare genetic disorders. Most recently, Dr. Cohn served as the Chief Medical Officer of Homology Medicines where he led the company’s Phase 1/2 gene therapy trial for phenylketonuria (PKU) and supported two investigational new drug (IND) submissions to U.S. Food and Drug Administration (FDA) for the company’s gene editing programs. Previously, he was Vice President of Clinical Development at AVROBIO, leading clinical programs, protocol design, regulatory filings, FDA and Health Canada interactions, and trial site identification and initiations. Dr. Cohn has also served in executive leadership roles at OvaScience and Shire. He is a Fellow of the American College of Genetics Genetics and Genomics (FACMG) and the American College of Obstetrics and Gynecology (ACOG), author of more than 40 peer-reviewed publications, and served as the Chief of Clinical and Reproductive Genetics and Medical Director, Genetic Services at Baystate Medical Center and as Assistant Professor at Tufts University School of Medicine. He earned his M.D. from SUNY Health Science Center at Syracuse and MBA from the Isenberg School of Management at the University of Massachusetts Amherst. He completed a residency in Obstetrics & Gynecology at SUNY HSC at Syracuse and a fellowship in Medical Genetics at the National Institutes of Health.
This person is not in any offices
iECURE
1 followers
iECURE is a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need. We believe our approach has the potential to replace and restore the function of a dysfunctional gene by knocking-in a healthy copy, regardless of mutation, to offer durable gene expression and long-term, potentially curative, therapeutic benefit. Our management team has extensive experience in executing global orphan drug and gene therapy clinical trials and successfully commercializing multiple products. We intend to leverage our team’s core strength in research and development strategy to identify what we believe to be the most suitable target and modality for our product candidates to address particular liver diseases. We are collaborating with the University of Pennsylvania’s Gene Therapy Program, or GTP, led by James M. Wilson, M.D., Ph.D., to utilize GTP’s world-class translational expertise and infrastructure, which has helped generate our initial pipeline of potential product candidates.